Catherine Wellan

Catherine Wellan

Auto-generated profile, based on publicly available information

Catherine Wellan

Clinical Laboratory, Evergreen Health, Monroe, Washington, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Pain Research and Management
Verified
Journal Article
Open access
EKErnest Kissi Kontor
Ernest Kissi Kontor
CWCatherine Wellan
Catherine Wellan
HMHafiz Mohammad Maaz
Hafiz Mohammad Maaz
DMDaha Garba Muhammad
Daha Garba Muhammad
Almonzer Al-QiamiAlmonzer Al-Qiami
Almonzer Al-Qiami
Nityanand JainNityanand Jain
Nityanand Jain
Background: Neuropathic pain (NP) is a chronic condition caused by abnormal neuronal excitability in the nervous system. Current treatments for NP are often ineffective or poorly tolerated. Hence, we reviewed the efficacy and safety of novel drugs or devices that target neuronal excitability in NP patients compared with placebo, sham, or usual care interventions.Methods: Six databases were searched for parallel randomized controlled trials (RCTs) reporting novel devices (rTMS, SCS, and TENS) or drugs (EMA401, capsaicin 8% patch, and Sativex) for NP. Data were extracted and quality was assessed using the ROB2 tool. The random‐effects inverse variance method was used for analysis.Results: In our review of 30 RCTs with 4251 participants, device‐based interventions were found to be more effective in reducing pain scores than control interventions (SMD = −1.27, 95% CI: −1.92 to −0.62). However, high heterogeneity was seen (p < 0.01, I2 = 91%), attributable to the etiology of NP (R2 = 58.84%) and year of publication (R2 = 49.49%). Funding source and type of control comparator were ruled out as cause of heterogeneity. Although drug interventions did not differ from placebo interventions in absolute pain reduction (SMD = −1.21, 95% CI: −3.55 to 1.13), when comparing relative change in pain intensity from baseline, drug interventions were found to be effective (SMD = 0.29, 95% CI: 0.04–0.55). Asymmetry in the funnel plot was visualized, suggesting publication bias. Certainty of evidence was very low according to GRADE assessment.Conclusions: Our review indicates that device‐based interventions are more effective than control interventions in reducing pain intensity in NP. Nevertheless, available evidence is limited due to heterogeneity and publication bias, prompting the need for more high‐quality RCTs to confirm the efficacy and safety of these interventions.

1 January 2024 in Canadian Journal of Kidney Health and Disease
Verified
Journal Article
Open access
ACAndrea C. Cowan
Andrea C. Cowan
KSKarla Solo
Karla Solo
VLVictoria Lebedeva
Victoria Lebedeva
YKYasaman Mohammadi Kamalabadi
Yasaman Mohammadi Kamalabadi
MEMaha El-Shimy
Maha El-Shimy
PRPavel S Roshanov
Pavel S Roshanov
Background: Kidney transplant recipients are uniquely exposed to the disordered bone metabolism associated with chronic kidney disease beginning before transplantation followed by chronic corticosteroid use after transplantation. Previous efforts to synthesize the rapidly accruing evidence regarding estimation and management of fracture risk in kidney transplant recipients are outdated and incomplete. Objective: To synthesize the evidence informing the overall incidence, patient-specific risk prediction, and methods of prevention of fractures in patient living with a kidney transplant. Design: Three systematic reviews will address the following questions: What is the overall incidence of skeletal fracture after kidney transplantation (review 1)? Which prediction models and individual prognostic factors predict fracture in kidney transplant recipients (review 2)? and How effective are different antifracture interventions at preventing fracture or improving surrogate markers of bone health in kidney transplant recipients (review 3)? Setting: Cohort studies (reviews 1 and 2) and randomized trials (review 2) with a mean/median follow-up ≥12 months beginning after transplant. Review 3: randomized trials or new-user cohort studies with concurrent controls evaluating the effect of antifracture interventions including bisphosphonates, calcium supplementation, cinacalcet, denosumab, parathyroid hormone analogues, parathyroidectomy, raloxifene, romosozumab, steroid withdrawal or minimization protocols after kidney transplant, vitamin D (both active and nutritional), other antifracture interventions. Patients: Adult kidney transplant recipients in studies published after the year 2000. Measurements: Review 1: incidence rate or cumulative risk of fracture. Review 2: For prediction models, measures of discrimination (eg, c-statistic), calibration (calibration curves, observed:expected ratios), and net benefit (ie, from decision curve analysis); for individual prognostic factors, relative measures of association with fractures. Review 3: measures of treatment effect on fractures and on surrogate markers of bone health (eg, bone mineral density, trabecular bone score). Methods: We searched MEDLINE, Embase, and the Cochrane Library using subject headings and keywords related to kidney transplant and fractures. Pairs of reviewers will screen records independently in duplicate to identify studies relevant to one or more of the 3 reviews and categorize each study accordingly. Single reviewers will extract data and evaluate risk of bias for each included study using one of the following tools as appropriate: the Quality of Prognostic Studies tool, the Prediction model Risk Of Bias ASsessment tool, the Risk Of Bias In Non-randomised Studies—of Interventions tool, and the Cochrane Risk of Bias 2.0 tool. A second reviewer will independently verify. We will synthesize study-level summary estimates by random-effects meta-analysis for review 1, by vote counting and random-effects meta-analysis in review 2, and by random effects pairwise and, if feasible, network meta-analysis in review 3. We will summarize findings according to latest guidance of the Grading of Recommendations Assessment, Development, and Evaluation Working Group applicable to each review. Limitations: Reliance on published studies is susceptible to publication bias, particularly in studies of prediction (review 2) and of treatment effects (review 3). Conclusions: This review will provide an evidence update on 3 topics of relevance to patients, clinicians, guideline developers, and researchers.